181 related articles for article (PubMed ID: 25692307)
1. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
2. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress.
Zhang Q; Zhou X; Wu R; Mosley A; Zeng SX; Xing Z; Lu H
Elife; 2014 Oct; 3():. PubMed ID: 25347121
[TBL] [Abstract][Full Text] [Related]
3. Global effect of inauhzin on human p53-responsive transcriptome.
Liao JM; Zeng SX; Zhou X; Lu H
PLoS One; 2012; 7(12):e52172. PubMed ID: 23284922
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex.
Liao JM; Zhou X; Gatignol A; Lu H
Oncogene; 2014 Oct; 33(41):4916-23. PubMed ID: 24141778
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.
Bhattarai N; Wang J; Nguyen D; Yang X; Helmers L; Paruch J; Li L; Zhang Y; Meng K; Wang A; Jayawickramarajah J; Wang B; Zeng S; Lu H
Theranostics; 2021; 11(14):7005-7017. PubMed ID: 34093867
[TBL] [Abstract][Full Text] [Related]
6. New Disubstituted Quindoline Derivatives Inhibiting Burkitt's Lymphoma Cell Proliferation by Impeding c-MYC Transcription.
Liu HY; Chen AC; Yin QK; Li Z; Huang SM; Du G; He JH; Zan LP; Wang SK; Xu YH; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
J Med Chem; 2017 Jul; 60(13):5438-5454. PubMed ID: 28603988
[TBL] [Abstract][Full Text] [Related]
7. Ribosomal protein S14 negatively regulates c-Myc activity.
Zhou X; Hao Q; Liao JM; Liao P; Lu H
J Biol Chem; 2013 Jul; 288(30):21793-801. PubMed ID: 23775087
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
9. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth.
Zhang Q; Ding D; Zeng SX; Ye QZ; Lu H
PLoS One; 2012; 7(10):e46294. PubMed ID: 23115626
[TBL] [Abstract][Full Text] [Related]
10. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.
Zhang Q; Zeng SX; Zhang Y; Zhang Y; Ding D; Ye Q; Meroueh SO; Lu H
EMBO Mol Med; 2012 Apr; 4(4):298-312. PubMed ID: 22331558
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activities of curcumin on human Burkitt's lymphoma.
Wu Y; Chen Y; Xu J; Lu L
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):348-52. PubMed ID: 12408761
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
[TBL] [Abstract][Full Text] [Related]
13. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
14. c-Myc inhibition negatively impacts lymphoma growth.
Gomez-Curet I; Perkins RS; Bennett R; Feidler KL; Dunn SP; Krueger LJ
J Pediatr Surg; 2006 Jan; 41(1):207-11; discussion 207-11. PubMed ID: 16410134
[TBL] [Abstract][Full Text] [Related]
15. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.
Goudarzi KM; Nistér M; Lindström MS
Cancer Biol Ther; 2014; 15(11):1499-514. PubMed ID: 25482947
[TBL] [Abstract][Full Text] [Related]
17. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.
Zhang Y; Zhang Q; Zeng SX; Hao Q; Lu H
Neoplasia; 2013 May; 15(5):523-34. PubMed ID: 23633924
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
19. The effects of a growth-inhibiting tripeptide, acetylGlu-Ser-GlyNH2 (Ac-ESG), on gene expression and cell cycle progression of two lymphoma cell lines.
Liu Y; Reichelt WH; Luna L; Elgjo K; Reichelt KL
Anticancer Res; 2003; 23(4):3159-65. PubMed ID: 12926049
[TBL] [Abstract][Full Text] [Related]
20. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
